OpenScience.ink

1 week ago • American journal of physiology. Endocrinology and metabolism

PYY3-36 may enhance Semaglutide's effects on energy control in fatty liver diseasePYY3-36 potentiates Semaglutide‑mediated mitochondrial modulation in MASLD.

🎖️ Top 10% JournalArticle

1 week ago • British journal of clinical pharmacology

How different doses of oral semaglutide affect artery stiffness and the added impact of SGLT-2 inhibitors in type 2 diabetesDose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.

📖 Top 20% JournalArticle

1 week ago • Obesity pillars

US workers' views and experiences with tirzepatide for obesity or overweight from the PERCEPTIONS SurveyEmployee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.

📖 Top 20% JournalArticle

1 week ago • Menopause (New York, N.Y.)

Weight loss treatments and sexual function in middle-aged women: possible role of GLP-1 medicinesWeight loss interventions and sexual function in midlife women: the emerging role of glucagon-like peptide-1 receptor agonists.

📖 Top 20% JournalArticle

1 week ago • Journal of the American College of Clinical Pharmacy : JACCP

Factors Influencing Prescribing of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Primary CareContextual Factors Affecting SGLT2 Inhibitors and GLP-1 Receptor Agonists Prescribing in Primary Care: An Application of the Consolidated Framework for Implementation Research.

📖 Top 50% JournalArticle

1 week ago • Journal of asthma and allergy

Risk of asthma attacks in diabetic patients with asthma using two different diabetes medicines in Hong KongGlucagon-Like Peptide-1 Receptor Agonists vs Dipeptidyl Peptidase-4 Inhibitor Use on Risk of Asthma Exacerbation Among Diabetic Patients with Co-Morbid Asthma in Hong Kong.

📖 Top 20% JournalArticle

1 week ago • Hepatology international

GLP-1 receptor drugs and their effects on fatty liver disease linked to metabolism: a review and combined analysis of clinical trialsGLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.

🥉 Top 5% JournalArticle

1 week ago • Journal of managed care & specialty pharmacy

Stopping glucagon-like peptide-1 receptor drugs among US adults: results from a national surveyDiscontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey.

📖 Top 20% JournalArticle

1 week ago • Pharmacological reviews

Combination peptide hormone treatments for long-term metabolic diseasesPeptide hormone-based combinational pharmacotherapies for chronic metabolic diseases.

🥇 Top 1% JournalArticle

1 week ago • Diabetes & metabolic syndrome

Changes in Eating Habits During Treatment with GLP-1 Receptor AgonistsNutritional intake changes during GLP-1 receptor agonist therapy: A systematic review and meta-analysis.

📖 Top 20% JournalArticle

1 week ago • Appetite

GLP-1 receptor drugs for obesity in teenagers during a key growth phaseGLP-1 receptor agonists in adolescent obesity: Incretin-based therapies during a sensitive developmental period.

📖 Top 20% JournalArticle

1 week ago • PharmacoEconomics

Cost-effectiveness of Semaglutide and Resmetirom (80 mg and 100 mg) Compared to Standard Treatment for Metabolic Liver Disease in the USA Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.

🎖️ Top 10% Journal

1 week ago • Journal of diabetes investigation

Differences between liraglutide and dulaglutide in causing or worsening eye and kidney problemsComparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications.

📖 Top 20% Journal

1 week ago • Kidney international

Different Kidney Benefits of GLP-1 Drugs in People with Type 2 DiabetesHeterogeneous Treatment Effects of GLP-1RA on Kidney Outcomes in Patients with Type 2 Diabetes.

🥈 Top 2% Journal

1 week ago • Diabetes

GIP Quickly Reduces Muscle Blood Flow Increases Caused by Insulin and GLP-1GIP Acutely Blunts Insulin- and GLP-1-Induced Muscle Microvascular Perfusion.

🥉 Top 5% Journal

1 week ago • ASAIO journal (American Society for Artificial Internal Organs : 1992)

Effects of Glucagon-like Peptide-1 Receptor Agonists in Obese Patients with Heart PumpsGlucagon-like Peptide-1 Receptor Agonists in Obese Left Ventricular Assist Device Recipients: A Propensity-Matched Real-World Cohort Study.

📖 Top 20% Journal

1 week ago • BMJ open

Availability, cost, and affordability of two diabetes treatments in 10 countriesAvailability, treatment costs and affordability of SGLT-2 inhibitors and GLP-1 RAs for diabetes in 10 countries: a cross-sectional study.

📖 Top 20% Journal

1 week ago • The Journal of biological chemistry

A sensor system for live, detailed detection of PYY hormone release from gut hormone-producing cellsA biosensor platform for scalable and live detection of PYY hormone production from enteroendocrine cells with single-event resolution.

🎖️ Top 10% Journal

1 week ago • Schizophrenia research

Effects of diabetes-related drugs on metabolism in schizophrenia patients taking antipsychoticsEffects of glucagon-like peptide-1 receptor agonists on metabolic outcomes in antipsychotic-treated patients with schizophrenia: A systematic review and meta-analysis.

📖 Top 20% Journal

1 week ago • JAMA network open

Glucagon-Like Peptide-1 Drugs and Risk of Fragile Bone Fractures in Type 2 DiabetesGlucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.

🥈 Top 2% Journal

1 week ago • BMJ open

Semaglutide to prevent type 2 diabetes in women with early diabetes risk after pregnancy diabetes: plan for a Belgian double-blind placebo-controlled trialSemaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.

📖 Top 20% Journal

1 week ago • Appetite

How activating or blocking one receptor differently affects effectiveness and side effects in obesity treatmentOne receptor, two opposite approaches: efficacy and tolerability of GIPR agonism and antagonism in obesity pharmacotherapy.

📖 Top 20% Journal

1 week ago • Journal of the neurological sciences

Use of glucagon-like peptide-1 receptor activators linked to severity of ischemic strokeAssociation between glucagon-like peptide-1 receptor agonist use and ischemic stroke severity.

📖 Top 20% Journal

1 week ago • JACC. Advances

Reduced Risk of Heart and Brain Blood Vessel Problems with Semaglutide Compared to TirzepatideCardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.

🎖️ Top 10% Journal

1 week ago • Obesity pillars

Satisfaction and experience with once-weekly tirzepatide treatment from doctors and people with obesity or overweightReal-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.

📖 Top 20% Journal

1 week ago • Journal of endocrinological investigation

New Findings on Protein Changes Linked to Semaglutide in Humans and AnimalsAdvances in proteomics research related to semaglutide: evidence from humans and animals.

📖 Top 20% Journal

2 weeks ago • JAMA network open

Starting Semaglutide Treatment in People Using Hormonal Birth ControlHormonal Contraception and Initiation of Semaglutide Therapy.

🥈 Top 2% Journal

2 weeks ago • Journal of endocrinological investigation

Survival and ongoing treatment in older adults with type 2 diabetes taking gliflozins or incretin drugsMortality and persistence in therapy in elderly subjects with type 2 diabetes receiving gliflozins or incretins.

📖 Top 20% Journal

2 weeks ago • Biological psychiatry

Possible Benefits of Incretin-Based Treatments for Alcohol Use Disorder Based on Clinical EvidenceTherapeutic Potential of Incretin-Based Therapies for Alcohol Use Disorder - A narrative review of available clinical evidence.

🥈 Top 2% Journal

2 weeks ago • Biological psychiatry

GLP-1 Receptor Drugs as a Possible Treatment for Opioid Addiction: Studies from Rats to HumansGLP-1 Receptor Agonists as a Candidate Treatment for Opioid Use Disorder: From rats to humans.

🥈 Top 2% Journal

← prevpage 6 of 14next →

GLP-1 Therapies Research Papers